The DOI matches its Crossref record.
Cognitive Outcomes and Long-term Follow-up Results after Enhanced Chemotherapy Delivery for Primary Central Nervous System Lymphoma
Abstract
OBJECTIVE: Patients with non-acquired immunodeficiency syndrome-related primary central nervous system lymphomas have the potential to achieve durable complete responses without radiotherapy, with treatment using enhanced chemotherapy delivery with blood-brain barrier disruption (BBBD). Reported 5-year survival rates with combined chemotherapy and radiotherapy were generally only 9 to 22% and were associated, in one study, with an overall 32% incidence of overt dementia and ataxia, which are dramatically increased among patients more than 60 years of age. METHODS: At the Oregon Health Sciences University, 111 consecutive patients with non-acquired immunodeficiency syndrome-related central nervous system lymphomas were prospectively treated with methotrexate-based, BBBD-enhanced chemotherapy and underwent formal neuropsychological evaluations. Of those, 74 patients had no systemic lymphoma and had received no prior irradiation; those 74 patients are described in this report. RESULTS: The estimated 5-year survival rate for this group was 42%, and the median survival time was 40.7 months. Overall, 48 patients (65%) exhibited complete responses and 36 patients continued to exhibit complete responses after 1 year of BBBD-enhanced chemotherapy. Of those 36 patients, none demonstrated evidence of cognitive loss in neuropsychological tests and/or clinical examinations. CONCLUSION: BBBD-enhanced chemotherapy delivery, without subsequent radiotherapy, resulted in favorable survival and cognitive outcomes for patients with primary central nervous system lymphomas who had not previously undergone irradiation. A cooperative multicenter study of intravenous chemotherapy without radiotherapy versus BBBD-enhanced chemotherapy would address the feasibility and necessity of performing a Phase III study for these rare central nervous system malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
DeAngelis, L. M., Seiferheld, W., Schold, S. C., Fisher, B., & Schultz, C. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.013 · Cited by 738
Batchelor, T., Carson, K., O’Neill, A., Grossman, S. A., Alavi, J., New, P., Hochberg, F., & Priet, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.036 · Cited by 546
Pels, H., Schmidt-Wolf, I. G. H., Glasmacher, A., Schulz, H., Engert, A., Diehl, V., Zellner, A., Schackert, G., Reichmann, H., Kroschinsky, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.056 · Cited by 427
Guillaume, D. J., Doolittle, N. D., Gahramanov, S., Hedrick, N. A., Delashaw, J. B., & Neuwelt, E. A. (2010) · PubMed · doi:10.1227/01.neu.0000363152.37594.f7 · Cited by 420
Self-citationChemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
Muldoon, L. L., Soussain, C., Jahnke, K., Johanson, C., Siegal, T., Smith, Q. R., Hall, W. A., Hynynen, K., Senter, P. D., Peereboom, D. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9861 · Cited by 417
Self-citation
Metadata
- Authors
- McAllister, L. D., Doolittle, N. D., Guastadisegni, P. E., Kraemer, D. F., Lacy, C. A., Crossen, J. R., & Neuwelt, E. A.
- Venue
- Neurosurgery
- Published
- 2000-01-01
- Volume
- 46
- Issue
- 1
- Pages
- 51-61
- ISSN
- 0148-396X (ISSN-L)
- 1524-4040
- OpenAlex
- W2026908425
- Cited by
- 239
- References
- 0
- FWCI
- 11.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cognitive Outcomes and Long-term Follow-up Results after Enhanced Chemotherapy Delivery for Primary Central Nervous System Lymphoma. https://app.cochat.ai/papers/10.1093/neurosurgery/46.1.51
- The paper
- McAllister, L. D., Doolittle, N. D., Guastadisegni, P. E., Kraemer, D. F., Lacy, C. A., Crossen, J. R., & Neuwelt, E. A. (2000). Cognitive Outcomes and Long-term Follow-up Results after Enhanced Chemotherapy Delivery for Primary Central Nervous System Lymphoma. Neurosurgery. https://doi.org/10.1093/neurosurgery/46.1.51
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.